Total Payments
$2,203
2023 Payments
$148.70
Companies
37
Transactions
154
Medicare Patients
1,507
Medicare Billing
$214,639
Payment Breakdown by Category
Food & Beverage$2,203 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,203 | 154 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $310.26 | 21 | $0 (2023) |
| PFIZER INC. | $173.26 | 19 | $0 (2022) |
| Lilly USA, LLC | $130.04 | 9 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $120.50 | 8 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $97.14 | 5 | $0 (2023) |
| Novo Nordisk Inc | $95.45 | 7 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $91.51 | 6 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $83.38 | 5 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $83.20 | 5 | $0 (2021) |
| Allergan, Inc. | $81.62 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $148.70 | 8 | Otsuka America Pharmaceutical, Inc. ($65.80) |
| 2022 | $764.04 | 50 | ABBVIE INC. ($220.13) |
| 2021 | $299.97 | 20 | AbbVie Inc. ($56.21) |
| 2020 | $216.02 | 15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($32.79) |
| 2019 | $153.42 | 11 | Kyowa Kirin, Inc. ($28.87) |
| 2018 | $319.78 | 28 | PFIZER INC. ($110.26) |
| 2017 | $301.17 | 22 | Boehringer Ingelheim Pharmaceuticals, Inc. ($79.37) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/11/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $26.84 | General |
| Category: PSYCHIATRY | ||||||
| 08/15/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: NEUROSCIENCE | ||||||
| 07/11/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug), NUEDEXTA | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: PSYCHIATRY | ||||||
| 04/04/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Bone Health | ||||||
| 02/27/2023 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: NEUROLOGY | ||||||
| 02/15/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Diabetes | ||||||
| 01/18/2023 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Diabetes | ||||||
| 12/19/2022 | Xeris Pharmaceuticals, Inc. | GVOKE PFS (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes | ||||||
| 12/06/2022 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/06/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: PRIMARY CARE | ||||||
| 11/18/2022 | Lilly USA, LLC | BAQSIMI (Drug), TRULICITY | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: Diabetes | ||||||
| 10/03/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Gastroenterology | ||||||
| 09/28/2022 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/09/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $15.72 | General |
| Category: PSYCHOLOGY | ||||||
| 09/07/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $11.20 | General |
| Category: NEUROSCIENCE | ||||||
| 08/30/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: NEUROSCIENCE | ||||||
| 08/12/2022 | Inogen, Inc. | InogenOne (Device) | Food and Beverage | Cash or cash equivalent | $20.79 | General |
| Category: Oxygen Concentrator | ||||||
| 08/08/2022 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $20.07 | General |
| Category: PSYCHOLOGY | ||||||
| 08/04/2022 | Merck Sharp & Dohme LLC | GARDASIL 9 (Biological), PNEUMOVAX 23, VAXNEUVANCE | Food and Beverage | In-kind items and services | $11.75 | General |
| Category: VACCINE | ||||||
| 08/02/2022 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: Diabetes | ||||||
| 08/02/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Diabetes | ||||||
| 07/27/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.43 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 538 | 1,059 | $182,040 | $77,879 |
| 2022 | 9 | 655 | 1,376 | $251,777 | $100,968 |
| 2021 | 5 | 128 | 267 | $45,417 | $19,986 |
| 2020 | 6 | 186 | 295 | $46,128 | $15,805 |
Total Patients
1,507
Total Services
2,997
Medicare Billing
$214,639
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 175 | 504 | $88,200 | $34,691 | 39.3% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 142 | 304 | $39,635 | $16,184 | 40.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 69 | 69 | $13,760 | $8,454 | 61.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Facility | 2023 | 41 | 41 | $6,685 | $5,023 | 75.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 46 | $11,500 | $4,234 | 36.8% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 34 | 34 | $8,500 | $3,377 | 39.7% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 24 | 24 | $7,680 | $3,317 | 43.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 15 | $3,000 | $1,355 | 45.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 22 | $3,080 | $1,245 | 40.4% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 155 | 574 | $100,450 | $39,591 | 39.4% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 145 | 146 | $46,720 | $18,388 | 39.4% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 139 | 340 | $44,200 | $17,529 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 47 | 85 | $21,250 | $10,200 | 48.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 45 | 73 | $14,560 | $6,014 | 41.3% |
| 99310 | Follow-up nursing facility visit per day, typically 35 minutes | Facility | 2022 | 48 | 56 | $14,000 | $5,709 | 40.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 40 | 60 | $8,400 | $2,731 | 32.5% |
| 99315 | Nursing facility discharge day management, 30 minutes or less | Facility | 2022 | 13 | 13 | $1,820 | $720.82 | 39.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 23 | 29 | $377.00 | $85.89 | 22.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 76 | $14,440 | $6,156 | 42.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 67 | $13,400 | $5,823 | 43.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 47 | $11,750 | $5,543 | 47.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 26 | 38 | $5,320 | $2,347 | 44.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 25 | 39 | $507.00 | $117.00 | 23.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 25 | 50 | $12,500 | $4,834 | 38.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 39 | 74 | $14,800 | $4,722 | 31.9% |
About Dr. Sam Ghoubrial, MD
Dr. Sam Ghoubrial, MD is a Internal Medicine healthcare provider based in Wadsworth, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1003892217.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sam Ghoubrial, MD has received a total of $2,203 in payments from pharmaceutical and medical device companies, with $148.70 received in 2023. These payments were reported across 154 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($2,203).
As a Medicare-enrolled provider, Ghoubrial has provided services to 1,507 Medicare beneficiaries, totaling 2,997 services with total Medicare billing of $214,639. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Wadsworth, OH
- Active Since 12/20/2005
- Last Updated 02/15/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1003892217
Products in Payments
- QULIPTA (Drug) $145.74
- VRAYLAR (Drug) $116.59
- NURTEC ODT (Drug) $109.22
- CHANTIX (Drug) $99.65
- XIFAXAN (Drug) $89.41
- UBRELVY (Drug) $83.67
- REXULTI (Drug) $77.07
- QELBREE (Drug) $74.58
- JARDIANCE (Drug) $73.28
- ENTRESTO (Drug) $72.15
- TRELEGY ELLIPTA (Drug) $67.90
- ELIQUIS (Drug) $62.19
- Ozempic (Drug) $53.51
- Nuedexta (Drug) $51.82
- NUEDEXTA (Drug) $51.63
- JANUVIA (Drug) $42.55
- NOURIANZ (Drug) $40.65
- UTIBRON (Drug) $35.78
- NAMZARIC (Drug) $35.38
- VYVANSE (Drug) $34.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Wadsworth
Dr. Michael Bianco, M.d, M.D
Internal Medicine — Payments: $8,824
Internal Medicine $8,824
Michael Lishnevski, M.d, M.D
Internal Medicine — Payments: $294.47
Internal Medicine $294.47
Dr. Jeffrey Lang, M.d, M.D
Internal Medicine
Internal Medicine
Mr. Lawrence Spoljaric, Md, MD
Internal Medicine
Internal Medicine